e-learning
resources
Virtual 2020
Pre-Congress Content
News on diagnosis and therapy of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
F. Mccormack (Cincinnati, United States of America), M. Yang (South San Francisco, United States of America), E. Morgenthien (South San Francisco, United States of America), C. Burg (South San Francisco, United States of America), J. Axmann (Basel, Switzerland), J. Stauffer (South San Francisco, United States of America)
Source:
Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Session:
News on diagnosis and therapy of idiopathic pulmonary fibrosis
Session type:
E-poster session
Number:
783
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Mccormack (Cincinnati, United States of America), M. Yang (South San Francisco, United States of America), E. Morgenthien (South San Francisco, United States of America), C. Burg (South San Francisco, United States of America), J. Axmann (Basel, Switzerland), J. Stauffer (South San Francisco, United States of America). Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF). 783
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD)
Source: Eur Respir J 2005; 26: Suppl. 49, 560s
Year: 2005
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP
Source: International Congress 2016 – IPF treatment I
Year: 2016
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Time-course changes in pulmonary haemodynamics in patients with idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation (LT)
Source: Eur Respir J 2004; 24: Suppl. 48, 668s
Year: 2004
Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Effects of a combination of pulmonary rehabilitation (PR) and non invasive ventilation (NIV) in patients with advanced interstitial lung disease (ILD)
Source: Annual Congress 2009 - Noninvasive ventilation in chronic respiratory failure
Year: 2009
Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD)
Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD
Year: 2011
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD).
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept